# Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)

> **NCT00139932** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 255 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** formoterol fumarate

## Key facts

- **NCT ID:** NCT00139932
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09-01
- **Primary completion:** 2006-11-21
- **Final completion:** 2006-11-21
- **Target enrollment:** 255 (ACTUAL)
- **Last updated:** 2017-03-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00139932

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00139932, "Tiotropium Bromide Alone vs Tiotropium Bromide and Formoterol Fumarate in Subjects With COPD (Study P04272)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00139932. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*